MA30584B1 - Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires - Google Patents

Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires

Info

Publication number
MA30584B1
MA30584B1 MA31561A MA31561A MA30584B1 MA 30584 B1 MA30584 B1 MA 30584B1 MA 31561 A MA31561 A MA 31561A MA 31561 A MA31561 A MA 31561A MA 30584 B1 MA30584 B1 MA 30584B1
Authority
MA
Morocco
Prior art keywords
following formula
prevention
treatment
cardiovascular diseases
dha ester
Prior art date
Application number
MA31561A
Other languages
English (en)
Inventor
Frederique Brune
Andre Delhon
Jean Gardette
Jean Francois Patoiseau
Alain Marty
Etienne Severac
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37686083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30584(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MA30584B1 publication Critical patent/MA30584B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/587—Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/02—Preparation of carboxylic acid esters by interreacting ester groups, i.e. transesterification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE L'ESTER DE L'ACIDE DOCOSAHEXAÉNOÏQUE AVEC UN ALCOOL CHOISI PARMI LES VITAMINES OU PROVITAMINES DU GROUPE B, AVANTAGEUSEMENT CONSTITUÉ PAR LE NICOTINOL DE FORMULE SUIVANTE LE PANTHÉNOL DE FORMULE SUIVANTE ET L'INOSITOL DE FORMULE SUIVANTE OU AVEC L'ISOSORBIDE DE FORMULE SUIVANTE : OU L'ISOSORBIDE MONONITRATE DE FORMULE SUIVANTE : ELLE CONCERNE ÉGALEMENT LEUR PROCÉDÉ DE PRÉPARATION, UNE COMPOSITION PHARMACEUTIQUE LES COMPRENANT ET SON UTILISATION DANS LE TRAITEMENT OU LA PRÉVENTION DES MALADIES CARDIOVASCULAIRES ET EN PARTICULIER DE LA FIBRILLATION AURICULAIRE.
MA31561A 2006-06-23 2009-01-09 Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires MA30584B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0605649A FR2902659A1 (fr) 2006-06-23 2006-06-23 Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires

Publications (1)

Publication Number Publication Date
MA30584B1 true MA30584B1 (fr) 2009-07-01

Family

ID=37686083

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31561A MA30584B1 (fr) 2006-06-23 2009-01-09 Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires

Country Status (38)

Country Link
US (2) US8034377B2 (fr)
EP (1) EP2034999B9 (fr)
JP (1) JP5053372B2 (fr)
KR (1) KR101380128B1 (fr)
CN (1) CN101472590A (fr)
AR (1) AR061622A1 (fr)
AT (1) ATE489091T1 (fr)
AU (1) AU2007262958B2 (fr)
BR (1) BRPI0713725A2 (fr)
CA (1) CA2655570C (fr)
CL (1) CL2010001123A1 (fr)
CO (1) CO6150156A2 (fr)
CR (1) CR10507A (fr)
DE (1) DE602007010776D1 (fr)
DK (1) DK2034999T3 (fr)
EC (1) ECSP099039A (fr)
ES (1) ES2355611T3 (fr)
FR (1) FR2902659A1 (fr)
GE (1) GEP20125464B (fr)
HN (1) HN2008001771A (fr)
HR (1) HRP20110086T1 (fr)
IL (1) IL195562A (fr)
MA (1) MA30584B1 (fr)
MX (1) MX2009000103A (fr)
MY (1) MY145985A (fr)
NO (1) NO20090334L (fr)
NZ (1) NZ573454A (fr)
PL (1) PL2034999T3 (fr)
PT (1) PT2034999E (fr)
RS (1) RS51629B (fr)
RU (1) RU2451672C2 (fr)
SA (1) SA07280345B1 (fr)
SI (1) SI2034999T1 (fr)
TN (1) TNSN08527A1 (fr)
TW (1) TWI389888B (fr)
UA (1) UA96156C2 (fr)
WO (1) WO2007147899A2 (fr)
ZA (1) ZA200900334B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2334536B1 (es) * 2008-04-11 2011-01-24 Universidad Complutense De Madrid Procedimiento para la obtencion selectiva de 12-hidroxi-9-cis-octadecenoato de (1,4:3,6-dianhidro-d-glucitol) utilizando lipasas inmovilizadas como catalizador.
FR2949063B1 (fr) * 2009-08-11 2011-09-30 Pf Medicament Composition pharmaceutique comprenant un ester de dha destinee a etre administree par voie parenterale
CN102946904A (zh) 2010-06-18 2013-02-27 埃克斯生物科技公司 关节炎治疗
FR2963790B1 (fr) * 2010-08-11 2012-09-28 Pf Medicament Docosahexaeneoate de panthenyle et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
PH12013500316A1 (en) 2010-08-23 2016-09-02 Janssen Biotech Inc Treatment for neoplastic diseases
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
CN102757444B (zh) * 2011-04-29 2016-02-10 南京信诺泰医药有限公司 具有一氧化氮供体性质的苯并呋喃类化合物
FR2998479B1 (fr) * 2012-11-27 2017-04-28 Pf Medicament Utilisation d'un ester de dha pour le traitement prophylactique et/ou curatif de la drepanocytose
WO2016024283A1 (fr) * 2014-08-12 2016-02-18 Praj Industries Limited Procédé pour la préparation de triglycérides de l'epa et du dha
US10441087B2 (en) 2015-02-24 2019-10-15 Sleep Number Corporation Mattress with adjustable firmness
JP7145162B2 (ja) 2017-02-16 2022-09-30 ヤンセン バイオテク，インコーポレイテッド 化膿性汗腺炎の処置
IL268804B2 (en) * 2017-02-20 2023-04-01 Univ Louisiana State Hydrogen sulfide and/or nitrite for the treatment and prevention of atrial fibrillation
CN110950881A (zh) * 2018-09-27 2020-04-03 中国科学院上海药物研究所 一类三环类似物、其制备方法和用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL133049C (fr) 1966-02-24
JPS5967263A (ja) 1982-10-07 1984-04-16 Terumo Corp ペンタエン高級脂肪酸ピリジルアルコ−ルエステルおよびその製法
JPS5967264A (ja) 1982-10-08 1984-04-16 Terumo Corp 血小板凝集抑制剤
EP0125252A1 (fr) * 1982-11-16 1984-11-21 MOTSCHAN, Georges Nouvelle utilisation d'une vitamine unique ou d'une combinaison de diverses vitamines
JPS6034947A (ja) * 1983-08-05 1985-02-22 Terumo Corp ドコサヘキサエン酸誘導体およびそれを用いた血小板凝集阻止剤
GB9300125D0 (en) * 1993-01-06 1993-03-03 Scotia Holdings Plc Compositions containing esters of unsaturated fatty acids
US5760081A (en) * 1994-05-10 1998-06-02 The General Hospital Corporation Omega 3 fatty acids in the prevention of ventricular fibrillation
CA2220091C (fr) 1995-05-01 2011-01-04 Scotia Holdings Plc Esters d'acide nicotinique et compositions pharmaceutiques contenant de tels esters
IL118092A0 (en) 1995-05-03 1996-09-12 Smithkline Beecham Plc Antibacterial compounds their preparation and pharmaceutical compositions containing them
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
AUPQ480399A0 (en) 1999-12-22 2000-02-03 Commonwealth Scientific And Industrial Research Organisation Unsaturated fatty acids and their uses in therapy
EP1157692B1 (fr) 2000-05-22 2005-10-05 Pro Aparts - Investimentos E Consultoria Lda Composition pharmaceutique d'acides gras, contenant au moins 80% en poids de EPA et DHA
ITMI20010129A1 (it) * 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
US7704542B2 (en) * 2001-09-12 2010-04-27 Xanodyne Pharmaceuticals, Inc. Vitamin/mineral compositions with DHA
US8729124B2 (en) * 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
ITMI20022511A1 (it) * 2002-11-26 2004-05-27 Victorix Assets Ltd Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale.
EP1466597A1 (fr) * 2003-04-07 2004-10-13 Clinigenetics Usage d'estères du dha pour le traitement des maladies vasculaires
WO2004091603A1 (fr) * 2003-04-07 2004-10-28 Clinigenetics Utilisation d’un ester de dha pour le traitement des malades cardiovasculaires
JP2006523642A (ja) 2003-04-17 2006-10-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 妊娠女性用のマルチ−ビタミンおよびミネラル補助剤

Also Published As

Publication number Publication date
WO2007147899A3 (fr) 2008-03-13
KR101380128B1 (ko) 2014-04-11
PT2034999E (pt) 2011-01-19
NO20090334L (no) 2009-03-04
PL2034999T3 (pl) 2011-05-31
TWI389888B (zh) 2013-03-21
MY145985A (en) 2012-05-31
ES2355611T3 (es) 2011-03-29
SI2034999T1 (sl) 2011-02-28
GEP20125464B (en) 2012-04-10
SA07280345B1 (ar) 2011-01-15
MX2009000103A (es) 2009-01-23
CR10507A (es) 2009-02-05
RU2008152248A (ru) 2010-07-27
HN2008001771A (es) 2011-01-24
ATE489091T1 (de) 2010-12-15
EP2034999B1 (fr) 2010-11-24
RS51629B (sr) 2011-08-31
TW200811108A (en) 2008-03-01
WO2007147899A2 (fr) 2007-12-27
DE602007010776D1 (de) 2011-01-05
ECSP099039A (es) 2009-02-27
EP2034999A2 (fr) 2009-03-18
JP5053372B2 (ja) 2012-10-17
AU2007262958A1 (en) 2007-12-27
EP2034999B9 (fr) 2011-03-09
CA2655570C (fr) 2015-09-08
US8034377B2 (en) 2011-10-11
AU2007262958B2 (en) 2011-10-27
CA2655570A1 (fr) 2007-12-27
KR20090024794A (ko) 2009-03-09
DK2034999T3 (da) 2011-01-24
ZA200900334B (en) 2009-12-30
US20090312354A1 (en) 2009-12-17
TNSN08527A1 (en) 2010-04-14
CO6150156A2 (es) 2010-04-20
BRPI0713725A2 (pt) 2012-10-30
CL2010001123A1 (es) 2011-03-25
IL195562A0 (en) 2009-09-01
AR061622A1 (es) 2008-09-10
IL195562A (en) 2012-06-28
CN101472590A (zh) 2009-07-01
HRP20110086T1 (hr) 2011-03-31
FR2902659A1 (fr) 2007-12-28
WO2007147899B1 (fr) 2008-05-02
JP2009544576A (ja) 2009-12-17
RU2451672C2 (ru) 2012-05-27
UA96156C2 (ru) 2011-10-10
NZ573454A (en) 2010-10-29
US20110237613A1 (en) 2011-09-29
US8227479B2 (en) 2012-07-24

Similar Documents

Publication Publication Date Title
Ginsburg et al. Saliva increases the availability of lipophilic polyphenols as antioxidants and enhances their retention in the oral cavity
WO2009091538A8 (fr) Composition pharmaceutique et méthode permettant de traiter l'hypertriglycéridemie et l'hypercholestérolémie chez des mammifères
WO2003013497A1 (fr) Compositions s'averant efficaces pour prevenir ou soulager des troubles ou maladies provoques par une hypofonction cerebrale
MA34169B1 (fr) Dérivés d'acide 1-amino-2-cyclopropyléthylboronique
MX348705B (es) Composiciones farmacéuticas y métodos de administración relacionados.
MA30914B1 (fr) Dihydropyrazolones substituees utilisees dans le traitement de maladies cardiovasculaires et hematologiques.
FR2878747A1 (fr) Utilisation d'acide(s) gras omega-3 pour le traitement de l'hypercholesterolemie causee par un traitement anti-retroviral chez les patients infectes par le vih
NO20090334L (no) DHA-estere og anvendelse derav i behandling og forebygging av kordiovaskulaer sykdom
NO20063328L (no) Anvendelse av en fettsyresammensetning som innbefatter minst en av EPA og DHA eller kombinasjoner derav
MA27093A1 (fr) Derives de sulfonamides, leur preparation et leur application comme medicaments.
EP1706106B1 (fr) Utilisation de compositions tres concentrees d'acides gras n-3 selectionnes destinees au traitement de troubles du systeme nerveux central
WO2011116139A3 (fr) Compositions pharmaceutiques améliorées et procédés d'administration
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
CA2392165A1 (fr) Analogues de la vitamine d
FR2952372B1 (fr) Nouveaux derives de mannopyranoside ayant une activite anticancereuse
BRPI0515209A (pt) compostos, composição cosmética, usos de uma composição e composição farmacêutica
FR2913885B1 (fr) Utilisation de la citrulline pour le traitement des pathologies liees a une augmentation de la carbonylation des proteines
KR20160091315A (ko) 다제내성 그램 양성균 항균제 및 외용제
WO2007056263A3 (fr) Methodes de traitement anticancereux avec des formulations d'un compose de platine a base de lipides d'une haute activite administrees par voie intraveineuse
WO2018085565A2 (fr) Peptides bioactifs courts bloquant l'activité des produits finaux de glycation avancée, compositions et procédés d'utilisation
US12558348B2 (en) Bioactive phytochemicals
JP6751868B2 (ja) 乳化組成物
Casu Photodynamic therapy against multidrug-resistant oral strains of Candida spp
WO2010047559A2 (fr) Formulations pharmaceutiques a liberation prolongee
MA29329B1 (fr) Derives d'amide en tant que ligands de canal ionique, compositions pharmaceutiques et methodes d'utilisation associees